CMN-005 by CoImmune for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

CMN-005 is under clinical development by CoImmune and currently in Phase II for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma).

Study finds gender disparity in quality of life for individuals with food allergies

Researchers examined the correlation between health-related quality of life (HRQL) and biological sex among individuals with immunoglobulin E (IgE)-related food allergies and their care providers.

February 9, 2024

Using deep brain stimulation to map dysfunctional brain circuits linked to four disorders

Mass General Brigham researchers identified sets of connections that are disrupted and malfunctioning as a consequence of Parkinson’s disease, dystonia, obsessive compulsive disorder and Tourette’s

February 24, 2024

Tracking the FDA advisory panel on the first CRISPR-based treatment for sickle cell disease

The Food and Drug Administration is convening a meeting of outside experts on Tuesday to review exa-cel, a CRISPR-based treatment for sickle cell disease made

October 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.